





Pharmaceutics 2021, 13, 1370. https://doi.org/10.3390/pharmaceutics13091370 www.mdpi.com/journal/pharmaceutics 
Article 
Improvement of Resveratrol Permeation through Sublingual 
Mucosa: Chemical Permeation Enhancers versus Spray Drying 
Technique to Obtain Fast-Disintegrating Sublingual 
Mini-Tablets 
Giulia Di Prima 1,*, Giuseppe Angellotti 1,2, Amalia Giulia Scarpaci 1, Denise Murgia 1, Fabio D’agostino 3, 
Giuseppina Campisi 2 and Viviana De Caro 1 
1 Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche (STEBICEF), University of 
Palermo, Via Archirafi 32, 90123 Palermo, Italy; giuseppe.angelloti@unipa.it (G.A.); 
amaliagiulia.scarpaci@unipa.it (A.G.S.); denise.murgia@unipa.it (D.M.); viviana.decaro@unipa.it (V.D.C.) 
2 Dipartimento di Discipline Chirurgiche, Oncologiche e Stomatologiche, Università degli Studi di Palermo, 
90127 Palermo, Italy; giuseppina.campisi@unipa.it 
3 Istituto per lo Studio degli Impatti Antropici e Sostenibilità dell’Ambiente Marino, Consiglio Nazionale delle 
Ricerche (IAS—CNR), Campobello di Mazara, 91021 Trapani, Italy; fabio.dagostino@cnr.it 
* Correspondence: giulia.diprima@unipa.it 
Abstract: Resveratrol (RSV) is a natural polyphenol with several interesting broad-spectrum 
pharmacological properties. However, it is characterized by poor oral bioavailability, extensive 
first-pass effect metabolism and low stability. Indeed, RSV could benefit from the advantage of the 
sublingual route of administration. In this view, RSV attitudes to crossing the porcine sublingual 
mucosa were evaluated and promoted both by six different chemical permeation enhancers (CPEs) 
as well as by preparing four innovative fast-disintegrating sublingual mini-tablets by spray drying 
followed by direct compression. Since RSV by itself exhibits a low permeation aptitude, this could 
be significantly enhanced by the use of CPEs as well as by embedding RSV in a spray-dried pow-
der to be compressed in order to prepare fast-disintegrating mini-tablets. The most promising ob-
served CPEs (menthol, lysine and urea) were then inserted into the most promising spray-dried 
excipients’ compositions (RSV-B and RSV-C), thus preparing CPE-loaded mini-tablets. However, 
this procedure leads to unsatisfactory results which preclude the possibility of merging the two 
proposed approaches. Finally, the best spray-dried composition (RSV-B) was further evaluated by 
SEM, FTIR, XRD and disintegration as well as dissolution behavior to prove its effectiveness as a 
sublingual fast-disintegrating formulation. 
Keywords: resveratrol; sublingual mucosa; spray drying; chemical permeation enhancers; menthol; 
lysine; urea; Transcutol®; sodium dodecyl sulfate; sodium dehydrocolate 
 
1. Introduction 
Nowadays, the use of natural compounds for prophylactic, co-adjuvant and thera-
peutic purposes receives a broad consensus. Indeed, nutraceuticals are generally char-
acterized by less side effects and lower production costs than synthetic drugs. In addi-
tion, the actual and always-growing knowledge in the fields of pharmacology, physiol-
ogy and immunonutrition highlights the effectiveness of natural compounds as alterna-
tive medicines or as helpful adjuvant therapeutic agents combined with conventional 
treatments. This is particularly true for resveratrol (RSV), a nutraceutical that exhibits 
interesting and broad-spectrum pharmacological activities that make it a promising 
candidate for potential applications in different fields [1–3]. RSV (active form: 
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3,4′,5-trihydroxy-trans-stilbene) is a phenolic phytoalexin obtained from red grapes, red 
wine and wild berries, as well as by both chemical and biotechnological synthesis [4]. 
Thanks to its molecular structure, RSV is able to bind different biomolecules, thus caus-
ing a wide range of potential therapeutic effects [5]. In particular, RSV has shown an-
ti-inflammatory, antioxidant, anticancer, cardioprotective and immunomodulatory 
properties; it seems to also be effective in treating neurodegenerative disorders and dia-
betes [1,6,7]. Furthermore, recent studies have also shown a promising antiviral activity 
that could result in being useful in the treatment of respiratory hyperinflammatory in-
fections, such as COVID-19 [8–10]. Despite its great potentiality, RSV is characterized by 
unfavorable physicochemical properties (e.g., aqueous solubility ≈ 0.05 mg/mL), insta-
bility (due to light exposure, alkaline pH and high temperature) and poor oral bioavail-
ability (< 1% due to extensive first-pass effect metabolism) [11–15]. Therefore, it is essen-
tial to find novel, alternative and innovative administration strategies in order to benefit 
from RSV’s therapeutic potential. In particular, the sublingual mucosa could be a useful 
alternative administration route as it allows direct absorption into the systemic circula-
tion and bypasses the first-pass hepatic metabolism, thus increasing the overall bioa-
vailability. The sublingual mucosa is a thin, non-keratinized tissue characterized by a 
high surface area (26.5 ± 4.2 cm2 if considering the sum of the ventral surface of the 
tongue together with the mouth floor) and extensive blood supply, which could assure 
fast onset of action and high plasma concentration [16–18]. When considering the 
transmucosal pathway, it might be useful to evaluate all the available strategies with 
which to enhance drug permeation across the tissues. These strategies could include 
conventional chemical enhancement and innovative technological approaches. The most 
frequently used conventional strategy involves the use of chemical permeation enhancers 
(CPEs), which are molecules that are able to effectively interact with the epithelia and 
transiently as well as reversibly modify their structure while promoting drug absorption 
[19–21]. The CPEs could be classified as follow: surfactants (e.g., sodium lauryl sulfate or 
sodium dodecyl sulfate), bile acids and their salts (e.g., sodium dehydrocolate), 
co-solvents (e.g., polyethylene glycol), positively charged amino acids (e.g., lysine and 
arginine), terpenes (e.g., menthol and limonene) and other molecules (e.g., urea and di-
ethylene glycol monoethyl ether, also known as Transcutol®) [22–28]. On the other hand, 
the accurate design of innovative drug delivery systems (DDSs) could represent an al-
ternative approach to promote drug permeation. In particular, fast-disintegrating sub-
lingual tablets are able to quickly disintegrate, once in contact with the saliva, before be-
ing swallowed. This leads to high drug concentration in situ and rapid absorption 
through the highly permeable sublingual mucosa. Moreover, fast-disintegrating sublin-
gual tablets should be extremely patient-friendly [16,29]. There are several technologies 
for the manufacturing of sublingual tablets, including spray drying, freeze drying, sub-
limation, direct compression and granulation processes. Among these, the spray drying 
technique represents an innovative strategy to obtain optimal pharmaceutical powders, 
characterized by homogeneous size distribution, shape, porosity, density, drug loading 
and chemical composition, which can be directly compressed in order to easily prepare 
sublingual tablets [30,31]. 
Based on these considerations, this study aims to evaluate the effectiveness of both 
the CPEs used and the innovative spray drying approach to enhance RSV sublingual 
permeation, and subsequently merge the two mentioned strategies in order to propose an 
optimized fast-disintegrating sublingual formulation. Firstly, the ability of RSV to cross 
the sublingual mucosa in the presence of six different CPEs was evaluated in order to 
identify the best ones. Contextually, by the spray drying technique, RSV-loaded phar-
maceutical powders were developed to finally produce RSV-loaded mini-tablets. 
Spray-dried powders also containing CPEs were then obtained and evaluated in the form 
of mini-tablets as well. Finally, the best composition in terms of increased solubility and 
sublingual permeation enhancement of RSV was further characterized to prove its effec-
tiveness as a sublingual fast-disintegrating formulation. 
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2. Materials and Methods 
2.1. Materials 
Trans-resveratrol (RSV) was purchased from A.C.E.F. Spa (Fiorenzuola D’Arda, It-
aly). Polyvinylpyrrolidone K90 (PVP K90), propylene glycol, sorbitol and lysine hydro-
chloride were obtained from Farmalabor (Canosa di Puglia, Italy). Urea, sodium dodecyl 
sulfate and menthol were supplied by Carlo Erba (Milan, Italy). Transcutol® was pur-
chased from Sigma-Aldrich Chemie (Steinheim, Germany). β-cyclodextrin (β-CD) was 
obtained from Roquette Italia S.P.A (Cassano Spinola, AL, Italy). Trehalose was pur-
chased from Hayashibara Shoij (Okayama, Japan). Polyethylene glycol 200 (PEG200) was 
purchased from Fluka (Rodano, Italy) and trifluoroacetic acid (TFA) was obtained from 
Merk (Darmstadt, Germany). A citrate buffer solution of 10 mM (pH 5.5) was prepared 
by dissolving 2.052 g of anhydrous sodium citrate and 0.636 g of citric acid monohydrate 
in 1 L of distilled water. Isotonic saline solution (0.9 % w/v) was prepared by dissolving 9 
g of sodium chloride (NaCl) in 1 L of distilled water. The isotonic saline solution con-
taining 5% w/v of trehalose was prepared by dissolving 9 g of NaCl and 50 g of trehalose 
in 1 L of distilled water. All chemicals and solvents were purchased from VWR Interna-
tional (Leuven, Belgium), were of analytical grade and were used without further puri-
fication. Porcine sublingual mucosae were kindly supplied by the Municipal Slaughter-
house of Villabate (Palermo, Italy). 
2.2. Methods 
2.2.1. CPEs to Promote RSV Sublingual Permeation 
Preliminary Stability Assay of RSV 
Considering the previously reported RSV solubility experiments and the literature 
data, stability studies were performed to assess the optimal experimental conditions for 
further analysis [4,13]. RSV (0.1% w/v) was dissolved in a citrate buffer solution (pH 5.5) 
and PEG200 mixture (80:20 v/v), with or without N-acetylcysteine (NAC) 0.2% (w/v). Each 
solution (10 mL) was kept in the dark at 37 ± 0.5°C under continuous stirring (Heidolph 
MR3001K Hotplate Stirrer with Heidolph EXT3001 Temperature Probe, Heidolph In-
struments, Schwabach, Germany) for 6 h. Every 30 min samples (500 µl) were withdrawn 
and analyzed to determine RSV concentration by both HPLC and UV-Vis methods. Each 
experiment was performed in triplicate. For the UV-Vis analysis a Shimadzu 1700 in-
strument (Japan) was used, and RSV was evaluated at λ = 305 nm. RSV standard solu-
tions in the citrate buffer solution (pH 5.5) and PEG200 mixture (80:20 v/v) were prepared 
to construct the calibration curve (concentration range: 0.00002–0.0080 mg/mL; y = 112.56 
x − 0.001; and R = 0.999). For HPLC-DAD analysis, a HPLC Agilent 1260 Infinity Instru-
ment equipped with a Quaternary Pump G1311B, a Diode Array Detector 1260 Infinity II 
and a computer integrating apparatus (OpenLAB CDS ChemStation Workstation) was 
used (injected volume: 20 µl; column temperature: 25 ± 1°C). Chromatographic separa-
tion was achieved on a reversed-phase column, Ace® Excel Super C18 (5U, 100A, size 125 
× 4.60 mm), and employed a 0.1% (v/v) TFA solution in water (solvent A) and acetonitrile 
(solvent B) by using the following time program: 0-2 min A:B = 70:30; 2-8 min A:B = 20:80; 
and 8-12 min A:B = 70:30. The flow rate was set at 1 mL/min and the UV wavelength at 
305 nm. In these conditions, the retention time of RSV was 5.3 min. Standard curves were 
used for the quantification of integrated areas under the peaks. The calibration curves 
were performed in the concentration range of 0.0001–0.01 mg/mL by injecting RSV 
standard solutions into methanol. Samples were injected after proper dilution. LOD and 
LOQ were 0.017 and 0.050 µg/mL, respectively. HPLC data were highly reproducible and 
linearly related to concentration (y = 87,308.09 x; R = 0.999). 
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Ex Vivo Evaluations 
• Tissue Preparation 
Porcine tongues were collected from freshly slaughtered domestic 12-month-old 
pigs (intended for human consumption) and immediately transferred to the laboratory in 
a refrigerated transport box within 1 h from animal sacrifice. The animal tissues were 
then washed in PBS, pH 7.4, and excised in order to remove any excess of tissue. The 
samples were placed in trehalose solution (5% w/v in isotonic buffer), left for 1 h and then 
kept at -80°C for at least one week. Before the ex vivo permeation studies, specimens 
were washed for 1 h in isotonic solution and then subjected to thermal shock in order to 
obtain the sublingual mucosa. Briefly, tissue samples were dipped for approximately 2 
min in a prewarmed isotonic solution (70°C), and the mucosa (80 ± 8 µm) was then 
carefully peeled off from the adipose tissue and submucosal connective tissue manually 
[32,33]. Mucosal specimen thickness was measured by using a digital micrometer (VWR 
International, Milano, Italy). 
• Ex Vivo Permeation Assay 
To evaluate RSV permeation throughout porcine sublingual mucosa, vertical 
Franz-type diffusion cells (PermeGear, flat flange joint, 9 mm orifice diameter and 15 mL 
acceptor volume, SES GmbH–Analysesysteme, Bechenheim, Germany) were used as a 
two-compartment open model. The obtained sublingual mucosa was equilibrated in the 
isotonic solution overnight at room temperature to remove all the biological matter 
which could interfere with the drug analysis. Afterwards, appropriate sections of mucosa 
were mounted between the acceptor and the donor chambers of Franz cells respectively 
filled with citrate buffer solution (pH 5.5) and 3% β-CD (w/v) citrate buffer (pH 5.5) and 
left to equilibrate at 37 ± 0.5 °C for 15 min. Hereafter, the citrate buffer was removed from 
the donor compartment and replaced with 1 mL of the solutions to be tested. At sched-
uled time intervals (15 min), samples (0.5 mL) were withdrawn from the acceptor com-
partment and immediately replaced with fresh acceptor fluid to maintain the sink condi-
tions. Each experiment was carried out at 37.0 ± 0.5°C, under continuous stirring, in the 
dark conditions for 3 h and repeated 6 times. The donor solutions analyzed were the 
following: RSV solution 1 mg/mL in a citrate buffer solution (pH 5.5) and PEG200 mixture 
(80:20 v/v); RSV 1 mg/mL and chemical permeation enhancer (CPE) 0.2 mg/mL (RSV:CPE 
= 5:1) solution in a citrate buffer solution (pH 5.5) and PEG200 mixture (80:20 v/v). The 
employed CPEs were sodium dodecyl sulfate (SDS), lysine hydrochloride (LYS), menthol 
(M), urea (U), sodium dehydrocolate (SDC) and Transcutol® (T). The amount of RSV 
permeated was quantified by UV-Vis analyses, after proper dilution of the recovered 
samples, by using a Shimadzu 1700 instrument (Japan). RSV standard solutions in 3% 
β-CD (w/v) citrate buffer (pH 5.5) were prepared to construct the calibration curve (λ = 
305 nm; concentration range: 0.0005–0.0075 mg/mL; y = 123.72 x − 0.02; and R = 0.999). 
Results are reported as means ± standard error (SE). 
• Evaluation of RSV Amount Entrapped in the Sublingual Tissue 
At the end of each permeation experiment, the Franz cells were disassembled and 
the porcine mucosa was collected to evaluate the amount of RSV entrapped in the tissue. 
Each sublingual mucosa specimen was washed with distilled water (3 x 2 mL) to remove 
any residue on its surface, and the RSV was then extracted by treating the tissue for 2 min 
with warmed (50–60°C) methanol (2 mL). The extraction was repeated 2 times. The ex-
traction liquors were collected, transferred to a 10 mL flask and brought to volume with 
methanol. The amount of drug extracted was quantified by UV-Vis analysis, after proper 
dilution of the recovered samples, by using a Shimadzu 1700 instrument (Japan). RSV 
standard solutions in methanol were prepared to construct the calibration curve (λ = 305 
nm; concentration range: 0.001–0.005 mg/mL; y = 143.38 x + 0.04; and R = 0.999). Results 
are reported as means ± standard error (SE). 
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Determination of the Biopharmaceutical Parameters: Js, Kp, tlag, De and Ac 
Drug flux (Js) through the sublingual tissue was calculated at the steady state per 




 (mg/cm2 × h−1 or µg/cm2 × h−1) (1) 
where Q is the amount of RSV (mg or µg) permeated during the time interval, t (h), and A 
is the area of sublingual mucosa in contact with RSV solutions (0.636 cm2). At the steady 
state Js is equal to the slope of the straight line obtained. The constant of permeability (Kp) 





where Cd is the starting RSV concentration loaded into the donor compartment. The tlag 
(min) was determined from the interception of the tangent to the linear portion of the 
permeation profile with the x-axis. 
Similarly, the amount of drug entrapped (De) per unit area in the mucosal tissue was 




 (mg/cm2 or µg/cm2) (3) 
where QT is the amount of RSV (mg or µg) entrapped in the tissue and A is the area 




 (cm) (4) 
where Cd is the starting RSV concentration loaded into the donor compartment [34,35]. 
The Origin 8.5 software was used for mathematical data processing. Results are ex-
pressed as means ± standard error (repetition of 6 experiments). 
2.2.2. Preparation and Ex Vivo Evaluation of RSV-Loaded Mini-Tablets 
Preparation of RSV-Loaded Pharmaceutical Powders by Spray Drying 
To prepare RSV-loaded pharmaceutical powders using the spray drying technique, 
5% (w/v) solutions that referred to the whole components in ethanol were prepared. 
2.5 g of the excipients and RSV in the appropriate ratios (Table 1) were dissolved in 
ethanol (50 mL). In order to obtain the pharmaceutical powders, a BUCH MINI Spray 
Dryer I B-290 equipped with an inert B-295 loop was used, setting the following param-
eters: an inlet temperature of 110°C, a solution flow of 100 mL/h, a nitrogen aspiration of 
100% and a cooling temperature (inert loop) of −20°C. Firstly, the instrument was equili-
brated with 30 mL of fresh ethanol, and subsequently the prepared samples were pro-
cessed. Afterwards, the instrument was cleaned with an additional 30 mL of fresh etha-
nol. Finally, the obtained powder was recovered. 
Table 1. Percentage composition of RSV-loaded pharmaceutical powders. 









RSV-A 59 20 6 - 15 
RSV-B 45 20 20 - 15 
RSV-C 49 30 6 - 15 
RSV-D 35 20 10 10 15 
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Characterization of the Pharmaceutical Powders: Yield Percentage, Drug Loading Per-
centage (DL%) and Loading Efficacy Percentage (LE%) 
Powders obtained by the spray drying technique were collected and immediately 
carefully weighed in order to calculate the yield as follows: 
Yield % =
obtained powder (g)
starting components amount (g)
× 100 (5) 
Subsequently, to determine the amount of RSV in the samples as well as the pow-
ders’ homogeneity, randomly selected aliquots (5 mg) were accurately weighted, dis-
solved in methanol in a 10 mL flask and brought to volume with methanol. The resulting 
clear solutions were appropriately diluted, filtered through a 0.22 µm nylon membrane 
and immediately analyzed by HPLC, as described above. The drug loading percentage 
(DL%) and the loading efficacy percentage (LE%) were then calculated as follow: 
DL% =
RSV (mg)
RSV− loaded powder (mg)
× 100 
LE% =
real RSV amount (mg)
theoretical RSV amount (mg)
× 100 
(6) 
Each analysis was performed in triplicate and the results are reported as means ± 
standard error. 
Preparation of RSV-Loaded Sublingual Mini-Tablets 
In order to obtain standardized samples in terms of weight, volume and amount of 
RSV, the powders produced by spray drying were compressed in order to obtain sub-
lingual tablets. Randomly selected aliquots of each powder were carefully weighed and 
directly compressed (6 tons) by using a hydraulic, single-die tableting machine (Perkin 
Elmer IR Accessory, Waltham, MA, USA), two flat-faced punches and a die [36]. To as-
sess the reproducibility of the preparation method and tablets’ (volume 0.2 cm3) uni-
formity in terms of weight, 6 tablets for each batch of powder were evaluated (analytical 
balance, Mettler Toledo AE240, Columbus, OH, USA). Results are expressed as means ± 
standard error. 
Ex Vivo Permeation Studies by Administering RSV-Loaded Sublingual Mini-Tablets 
The ex vivo permeation studies by administering RSV-loaded sublingual 
mini-tablets were carried out analogously as described in paragraph 2.2.2. A sublingual 
mini-tablet was loaded into the donor compartment and soaked with 300 µl of citrate 
buffer (pH 5.5), while 15 mL of 3% β-CD (w/v) citrate buffer was used as acceptor fluid. 
At the end of each permeation experiment the donor medium was withdrawn, centri-
fuged, appropriately diluted in methanol and analyzed by HPLC (as described above) to 
determine the actual RSV concentration in the donor chamber. These data were em-
ployed as correct Cd values to calculate the Kp and Ac parameters. Moreover, at the end 
of experiments each mini-tablet was subjected to visual and tactile inspections in order to 
verify its integrity. Finally, the amount of RSV entrapped in the sublingual tissue was 
extracted and quantified as described above. The previously described biopharmaceuti-
cal parameters were calculated as reported above. Results are expressed as means of six 
experiments ± standard error. 
Preparation and Characterization of CPE-Loaded Sublingual Mini-Tablets 
The compositions indicated as RSV-B and RSV-C were chosen to include some se-
lected CPEs (lysine hydrochloride, urea or menthol—ranging from 1 to 3% w/v), conse-
quently reducing the PVP K90 amount necessary to maintain RSV–excipients ratios, as 
reported in Table 2. However, as LYS is insoluble in ethanol, to prepare the solution 
containing this CPE it was necessary to first dissolve LYS in 1.5 mL of bidistilled water 
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and then add the clear solution to the ethanol solution of the other components to avoid 
LYS precipitation. 
Table 2. Composition (as w/w percent) of RSV-loaded pharmaceutical powders that include the 
selected CPEs. 














RSV-B/LYS-3 45 20 20 15 3 - - 
RSV-B/M-3 45 20 20 15 - 3 - 
RSV-B/U-3 45 20 20 15 - - 3 
RSV-B/U-1 45 20 20 15 - - 1 
RSV-C/LYS-3 49 30 6 15 3 - - 
Powders obtained were collected and immediately weighed to evaluate the yield 
percentage and the loaded amount of RSV by HPLC analysis as described above. Finally, 
the prepared CPE-loaded powders were directly compressed as already reported and the 
obtained CPE-loaded sublingual mini-tablets were used to perform the ex vivo permea-
tion studies. 
2.2.3. Characterization of RSV-B Powder and Sublingual Fast-Disintegrating Mini-Tablets 
Scanning Electron Microscopy (SEM) Analysis 
SEM measurements were carried out using a Zeiss EVO MA10 (Carl Zeiss Micros-
copy GmbH, Jena, Germany) scanning electron microscope, equipped with an Everhart–
Thornley secondary electron detector (source of electrons was a lanthanum hexaboride 
LaB6 cathode). The accelerating voltage, 20 keV, and the probe voltage were 10 pA. The 
scanning electron microphotographs were acquired in an ultra-vacuum condition (HV, 
about 10−7 mbar) and at various magnification values. RSV-B powder was loaded on an 
aluminum stub and then coated with an ultrathin layer of gold (thickness about 2 nm) 
with an AGAR Sputter Coater-type system to increase the surface electrical conductivity. 
Fourier Transform Infrared Spectroscopic in Attenuated Total Reflectance Mode 
(FTIR-ATR mode) Evaluations 
FTIR-ATR mode spectra were recorded on a Fourier transform infrared spectrome-
ter (Nicoret iS5, Thermo Scientific™, Waltham, MA, USA) equipped with a ZnSe ATR 
unit ID7 (Thermo Scientific™, USA) for surface analysis. Spectra were collected by the 
accumulation of 32 scans in the 4000-500 cm-1 range and rationed to the appropriate 
background spectra. Both pure RSV as well as the PVP K90 and RSV-B formulation were 
analyzed in order to evaluate any interaction. 
X-ray Diffraction (XRD) Analysis 
Pure RSV and the RSV-B formulation were evaluated by an X-ray diffractometer 
suitable for powders (D-8 Focus, Brucker, USA). The diffraction angles were scanned 
from 5° to 60° in θ/2θ at 2°/min, 40 kV voltage and 30 mA current at room temperature. 
XRD analyses were performed immediately after RSV-B powder preparation as well as 
after six months of storage at room temperature in the dark. 
Disintegration Studies 
In order to evaluate the disintegration time (DT) of the RSV-B mini-tablets, two dif-
ferent tests were performed. 
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• In Vitro Disintegration Test 
To determine the DT a USP disintegration tester was used. The disintegration me-
dium consists of 900 mL of distilled water heated at 37 ± 0.5 °C and stirred at 100 rpm 
[16]. The time required to observe the complete disintegration of each mini-tablet was 
recorded in seconds. Results are expressed as means of 6 experiments ± standard error. 
• In Vitro Disintegration Visual Test 
To better simulate the in vivo conditions a visual test was conducted. A mini-tablet 
was inserted into a glass crucible and soaked with 1 mL of citrate buffer solution (pH 5.5) 
prewarmed at 37 ± 0.5 °C. During the experiment both multiple photographs and short 
videos (normal speed or slow motion) were collected in order to visually assess the 
complete disintegration. The experiment was repeated for 6 randomly selected 
mini-tablets. 
• In Vitro Dissolution Test 
Dissolution tests were performed to evaluate the amount of RSV released over time. 
The tests were performed on 6 randomly selected RSV-B mini-tablets according to USP 
procedure using a USP apparatus type II method at a paddle speed of 50 rpm [16]. The 
dissolution medium consisted of 500 mL of citrate buffer (pH 5.5) at 37 ± 0.5 °C. At 
scheduled time intervals (2, 5, 8, 10, 15, 20 and 25 min) samples (1 mL) were withdrawn 
and replaced with fresh citrate buffer. The collected samples were centrifuged and the 
RSV amount was determined by UV-Vis analysis, as described above. 
2.2.4. Data Analysis 
Data were expressed as means ± SE. All differences were statistically evaluated by 
the Student’s t-test with the minimum levels of significance, with p < 0.05. 
3. Results and Discussion 
3.1. Evaluation of CPEs to Promote RSV Sublingual Permeation 
Considering the interesting broad-spectrum activities of RSV as well as its disad-
vantageous physicochemical properties, it is common to propose the use of alternative 
routes of administration aimed at overcoming the existing limits. In this context, the use 
of the sublingual route should show promising results. However, it is necessary to first 
evaluate the aptitude of RSV to cross the selected epithelial tissue by itself, as penetration 
and subsequent permeation phenomena are indispensable to ensure systemic effects. The 
main strategy to assess the permeability of an active ingredient through a biological 
membrane/tissue involves the use of a two-compartment open model (e.g., Franz-type 
diffusion cells) accompanied by a membrane that could be synthetic and accurately de-
signed to simulate the biological tissue or could be a biological specimen [34,37–39]. 
Moreover, when evaluating the permeability of poorly water-soluble molecules, it is 
crucial to ameliorate their solubility into the donor compartment to increase the concen-
tration gradient, which is indispensable in establishing the permeation phenomenon. In 
addition, it is also crucial to select an acceptor fluid in which the drug is freely soluble to 
be sure that any limitation in terms of permeation is just due to the characteristics of the 
drug instead of restrictions by the saturation of the acceptor medium. Previous studies 
confirmed the usefulness of citrate buffer solution (pH 5.5) to stabilize and of 
β-cyclodextrins (3% w/w, β-CD) to promote solubility of RSV [4]. Nevertheless, the β-CD 
solution in citrate buffer tends to give rise to precipitation phenomena if not subjected to 
constant agitation and, consequently, it was not used as donor fluid as it led to a variation 
in the effective area of the mucosa available to permeation, thus producing misleading 
results. 
Therefore, in order to find an effective strategy with which to load high RSV con-
centrations into the donor chamber, the following parameters were considered: RSV sta-
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bility is enhanced at acidic pH values; RSV is extremely poorly water-soluble (logP = 3.1; 
water solubility = 0.05 mg/mL); and RSV is extremely soluble in polyethylene glycol (e.g., 
PEG400 solubility = 373.85 mg/mL) [13,14]. In particular, the mixture of citrate buffer so-
lution (pH 5.5) + PEG200 (80:20 v/v) was proposed, as it was able to easily dissolve high 
RSV concentrations (1 mg/mL). To evaluate the usefulness of the proposed mixture, RSV 
stability studies were performed both with and without NAC, which is used as a pre-
servative agent for polyphenols [40]. Stability studies were performed in the dark for 6 h 
at 37 ± 0.5 °C and the amount of RSV in each sample was quantified by both UV-Vis as 
well as HPLC analyses. As reported in Figure 1, RSV remains stable in both cases for the 
whole time considered and, consequently, the mixture without NAC was selected for 
further ex vivo evaluations. 
 
Figure 1. RSV stability studies on (A) the citrate buffer (pH 5.5) and PEG200 mixture (80:20 v/v) and (B) also in presence of 
NAC (RSV: NAC = 1:2). RSV was quantified by UV-Vis (black) and HPLC (red) analyses. Results are presented as means ± 
SE (n = 3). 
Once selected, both the donor and the acceptor fluids (citrate buffer + PEG200 mixture 
and the 3% β-CD dispersion in citrate buffer, respectively) ex vivo permeation studies in 
the absence and presence of six selected CPEs were performed. In particular, the fol-
lowing CPEs belonging to different chemical classes were used: 
• Sodium dodecylsulfate (SDS). It is a widely used anionic surfactant consisting of a 
hydrophobic tail (C12) linked to a hydrophilic sulfate group. It appears as a white 
crystalline powder, is quite soluble in water and ethanol and is often used in the 
cosmetic and pharmaceutical fields to promote solubility as well as absorption of ac-
tives through epithelial membranes, e.g., skin and gastrointestinal mucosa. The 
permeation enhancer effects are attributable to the alteration of the ordered state of 
the extracellular lipids by solubilization [23,24,41]; 
• Sodium dehydrocolate (SDC). It belongs to the class of biliary salts/acids which are 
defined as amphipathic ionic biosurfactants with a steroid structure, as they are 
synthesized in the liver from cholesterol. Thanks to its high biocompatibility, it could 
be widely used as a permeation enhancer through skin buccal, nasal, lung and intes-
tinal tissues. Moreover, it exerts chemical and enzymatic stabilization of drugs. The 
absorption enhancement effect is due to the extraction of membrane proteins, inter-
action with the lipid component of the membranes and the formation of inverse mi-
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celles which reversibly increase the fluidity of the apical and basolateral membranes, 
thus facilitating the passage of drugs [22,42]; 
• Transcutol® (T). It is also known as diethylene glycol monoethyl ether. It is a clear 
liquid characterized by low viscosity, a stability between pH 4-9 and a pleasant odor. 
It acts as a permeation enhancer by improving drug solubility inside the membranes 
(alteration of the partition coefficient) rather than directly increasing the drug diffu-
sivity [43]; 
• Lysine hydrochloride (LYS). It is a cationic amino acid that belongs to the twenty 
essential amino acids and, consequently, it is biocompatible, safe and non-toxic. Its 
chemical permeation enhancement effect is mainly due to the establishment of ionic 
interactions with the charged groups of the mucosal membrane, thus increasing the 
diffusion process. Furthermore, lysine could benefit from the amino acid transporters 
and consequently direct active substances through the epithelial layers [26,44]; 
• Urea (U). It is a biocompatible organic compound that appears as a colorless crystal-
line solid. Numerous studies have depicted its permeation enhancement ability be-
cause of its highly moisturizing power (ability to recall and retain water). Moreover, 
urea is also able to increase the fluidity of the phospholipid bilayer while maintaining 
the integrity of the membrane protein domains [27]; 
• Menthol (M). It belongs to the terpenes, which are reported as permeation promoters 
obtained from natural sources and widely included on the Food and Drug Admin-
istration (FDA) list of safe agents. The permeation enhancement power of terpenes is 
mainly linked to their chemical structure and their physicochemical properties. In 
particular, menthol is able to increase the interaction with the non-polar membranes 
and it is also useful as a flavoring agent, thus increasing patients’ compliance [45]. 
For each set of the permeation experiments the RSV concentration was kept constant 
(1 mg/mL), as was the RSV:CPE ratio (5:1). Drug permeation profiles are reported in 
Figure 2, while Figure 3 shows the amount of RSV entrapped in the sublingual tissue at 
the end of the permeation experiments. To singularly observe the permeation profiles 
please check the supplementary materials (from Figure S1 to Figure S7). Finally, Table 3 
highlights the calculated biopharmaceutical parameters. 
 
Figure 2. RSV permeation profiles in the absence and in the presence of CPEs. RSV (mg/cm2) per-
meated as a function of incubation time (h) after administration of RSV solution 1 mg/mL (black) 
and RSV solution 1 mg/mL + 0.2 mg/mL of sodium dodecylsulfate (red), sodium dehydrocolate 
(blue), Transcutol® (pink), lysine hydrochloride (orange), urea (light blue) and menthol (green). 
Results are presented as means ± SE (n = 6). 
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As is observable, each of the selected CPEs is capable of promoting RSV permeation 
through the sublingual mucosa as well as its accumulation in the tissue. As reported, the 
enhancement in terms of drug flux follows the trend RSV < RSV+T < RSV+SDC < 
RSV+SDS < RSV+U < RSV+LYS < RSV+M, while the promotion of tissue accumulation 
follows the trend RSV < RSV+T < RSV+U < RSV+LYS < RSV+M < RSV+SDS < RSV+SDC. 
These data generally confirm that Transcuol® exhibits the lowest permeation/penetration 
enhancement activity. Moreover, it is likely noticeable that SDS and SDC are better at 
promoting tissue accumulation rather than drug permeation. However, it is generally 
observable that the flux increase is accompanied by a variation/reduction in the calcu-
lated tlag value. 
 
Figure 3. Amount (mg) of RSV accumulated in the sublingual tissue after 3 h by administering RSV 
solution 1 mg/mL (black) and RSV solution 1 mg/mL + 0.2 mg/mL of sodium dodecylsulfate (red), 
sodium dehydrocolate (blue), Transcutol® (pink), lysine hydrochloride (orange), urea (light blue) 
and menthol (green). Results are presented as means ± SE (n = 6). 
Table 3. Extrapolated RSV biopharmaceutical parameters (Js, Kp, tlag, De and Ac) in the absence or 
in the presence of the selected CPEs. Values are presented as means ± SE (n = 6). 
 Js (mg/cm2∙h−1)= Kp (cm/h) * tlag (min) De (mg/cm2)=Ac (cm) * 
RSV 0.01376 ± 0.00311 19 min 0.02271 ± 0.00554 
RSV+T 0.01829 ± 0.00347 29 min 0.03086 ± 0.00883 
RSV+SDC 0.02139 ± 0.00401 11 min 0.08435 ± 0.00922 
RSV+SDS 0.02718 ± 0.00286 26 min 0.04108 ± 0.00510 
RSV+U 0.03226 ± 0.00220 22 min 0.03203 ± 0.00622 
RSV+LYS 0.03247 ± 0.00067 5 min 0.03384 ± 0.01013 
RSV+M 0.04780 ± 0.00896 – 0.03472 ± 0.00553 
*, Js = Kp and De = Ac because Cd = 1 mg/mL. 
To briefly summarize, the best permeation enhancement activity was exerted by 
menthol, lysine and urea, which increase RSV flux through the mucosa up to 3.5, 2.4 and 
2.3 times, respectively, which correspond to an increase of up to 247.4%, 136.0% and 
134.5% in terms of Kp value. These CPEs were then selected to be added to the most 
promising spray-dried compositions as they represented the best lipophilic CPE (men-
thol), the best hydrophilic pH-dependent CPE (lysine) and the best hydrophilic 
pH-independent CPE (urea). 
Pharmaceutics 2021, 13, 1370 12 of 26 
 
 
3.2. Preparation and Characterization of RSV-Loaded Mini-Tablets by Spray Drying Technique 
At this point, the second aim of the present work was to develop RSV-loaded 
spray-dried powders suitable for preparing mini-tablets for sublingual application. This 
goal is based on the potential effectiveness of innovative sublingual DDSs capable of 
improving RSV solubility, stability, administrability and consequently, permeability. 
Sublingual mini-tablets were selected as a suitable innovative dosage form as they were 
optimal vehicles in which to load a large amount of drug. The key factor in producing 
appropriate sublingual solid formulations is to start from a homogeneous powder, and 
thus the spray drying technique was chosen to prepare four different powders in terms of 
composition/excipients ratios, as reported in the Materials and Methods section. In par-
ticular, the prepared powders (named RSV-A, RSV-B, RSV-C and RSV-D) were com-
posed by a fixed RSV amount (15% w/w) and different ratios of the following excipients: 
PVP K90, PEG200, sorbitol and propylene glycol. The main component of the proposed 
formulations is polyvinylpyrrolidone K90 (PVP K90). It is a synthetic polymer consisting 
of 1-vinyl-2-pyrrolidone monomers, soluble in water, alcohols and other polar solvents. 
Thanks to its versatility, PVP K90 is a widely used excipient in the pharmaceutical, food 
and cosmetic industries. Indeed, PVP K90 is a biodegradable, stable and non-toxic pol-
ymer, able to interact with both hydrophilic and lipophilic molecules and is therefore 
useful for the development of conventional as well as innovative DDSs. PVP K90 is also 
used to improve the solubility and enhance the dissolution rate and thus the bioavaila-
bility of poorly water-soluble actives. Furthermore, it increases the physical stability of 
amorphous drug forms by preventing crystallization. Additionally, PVP K90 is often 
used to prepare mucosal DDSs due to its mucoadhesive properties [46,47]. To promote 
RSV solubilization into the buccal environment, PEG200 was chosen as the secondary 
polymer. PEGs are characterized by high structural flexibility (without any steric hin-
drance), biocompatibility and high hydration capability. In addition, they are biode-
gradable polymers with a well-established safety profile, being approved by the FDA. In 
particular, PEG200 was chosen due to its solubilizing/stabilizing and taste-masking prop-
erties as well as its ability to act as a promoter of drug bioavailability [48,49]. In designing 
fast-disintegrating formulations the role of the disintegrating agent is significant, which, 
in this work, was identified as sorbitol. Sorbitol is the alditol of glucose. It is a hydrophilic 
molecule capable of attracting and retaining water, thus determining the fast dissolution 
of formulations on the application site and promoting in situ high drug concentration. It 
is widely used in the food industry for its sweetening power (about 60% of sucrose) and 
its role as a stabilizer and leavening agent. Its interesting properties also make it very 
useful in the pharmaceutical field. In this context, sorbitol proved to be an advantageous 
excipient in the production of sublingual fast-disintegrating tablets, being capable of 
rapidly disaggregating into the small salivary volumes and contextually showing 
pleasant organoleptic characteristics [50]. Finally, only in the RSV-D formulation was 
propylene glycol added. It is an odorless, colorless and viscous liquid, characterized by a 
sweetish taste, hygroscopicity and miscibility with different solvents. It is widely used in 
the food, cosmetic and pharmaceutical fields as an additive, plasticizer, humectant and 
solubilizer. In this work it was selected as it can act as an excellent cosolvent to increase 
RSV solubility, thus synergizing with the effect of PEG200 [51]. 
To summarize: the RSV-A formulation could be considered the basic one, RSV-B is 
characterized by the highest amount of sorbitol, RSV-C comprised the largest amount of 
PEG200 and RSV-D is the formulation that includes propylene glycol as an excipient. The 
different compositions resulted in different spray-dried powder appearances. In partic-
ular, RSV-A (see supplementary material: Figure S8, panel A) and RSV-B had soft and 
light powders while RSV-C (see supplementary material: Figure S8, panel B) and RSV-D 
lead to very fine and dense powders. 
In order to evaluate the suitability of the spray drying technique and verify the em-
ployment of the correct procedure parameters, each obtained powder was subjected to 
yield %, DL% and LE% evaluations. The results are reported in Table 4 and highlight the 
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successful application of the spray drying method. Indeed, the yield % of around 70% 
w/w is a really high value as, according to the literature, a significant disadvantage of the 
spray drying process concerns a non-optimal atomization yield (20-70%) due to the 
product loss in the walls of the drying chamber and the low ability of the cyclone in 
separating the fine particles [31]. Moreover, the obtained DL% and LE% values con-
firmed the homogeneity of the prepared powders and the reproducibility of the prepa-
ration method. The data obtained by HPLC-DAD analysis also proved that RSV exposure 
to the high operating temperature (110 °C) did not involve any alteration and/or degra-
dation. In fact, the RSV retention time and UV-Vis spectrum were identical to the RSV 
standard. Neither additional chromatographic peaks nor alterations in the shape of the 
UV spectrum at wavelengths between 200 and 700 nm were observed during quantifica-
tion analyses [52]. This evidence ruled out any doubt in the maintenance of RSV stability 
during the production process. 
Table 4. Characterization of the spray-dried powders in terms of yield %, DL% and LE% ± SE (n = 
3). 
Composition Yield % DL% LE% 
RSV-A 76.0  16.54 ± 1.06  110.29 ± 7.09  
RSV-B 82.0  11.06 ± 0.67  73.71 ± 4.50  
RSV-C 64.4  15.41 ± 0.44  102.73 ± 2.95  
RSV-D 67.6  15.67 ± 0.33  102.44 ± 2.22  
The prepared powders were then directly compressed in order to produce sublin-
gual mini-tablets (see supplementary material: Figure S9) that were homogeneous in 
terms of weight and RSV content (Table 5), thus confirming the reproducibility of the 
direct compression method. 
Table 5. RSV-loaded sublingual mini-tablets: weight and drug content ± SE (n = 6). 
Formulation Weight (mg) RSV per Mini-Tablet (mg) 
RSV-A mini-tablet 29.96 ± 0.38 4.96 ± 0.06 
RSV-B mini-tablet 30.60 ± 0.47 3.28 ± 0.05 
RSV-C mini-tablet 30.59 ± 0.12 4.71 ± 0.02 
RSV-D mini-tablet 30.82 ± 0.40 4.74 ± 0.06 
The prepared mini-tablets were used to evaluate RSV permeation when embedded 
into the proposed formulation by using Franz-type vertical diffusion cells and porcine 
sublingual mucosae as membrane models. Each mini-tablet was placed into the donor 
chamber and soaked with 300 µl of citrate buffer solution (pH 5.5). To better understand 
the obtained results (Figure 4 and Table 6) it is important to consider the extremely low 
water solubility of RSV. Indeed, to correctly calculate the Kp and Ac parameters, the ac-
tual RSV concentration in the donor chamber was evaluated and considered at the end of 
each permeation experiment. Moreover, after permeation studies, the mini-tablets were 
subjected to visual and tactile inspections. As expected, the variations in terms of com-
position resulted in different behaviors. RSV-A mini-tablets absorbed water from the 
surrounding environment and became rubbery, similar to chewing gum; RSV-B 
mini-tablets completely disintegrated once in contact with the donor media (as they 
contain the highest amount of sorbitol); and RSV-C as well as RSV-D mini-tablets were 
only partially disintegrated, and some solid residues were extremely crumbly to the 
touch. 




Figure 4. (A) RSV permeation profiles: RSV (mg/cm2) permeated as a function of incubation time 
(h). (B) Kp and (C) Ac parameters, calculated after administration of RSV solution 1 mg/mL (black), 
RSV-A mini-tablet (blue), RSV-B mini-tablet (red), RSV-C mini-tablet (green) and RSV-D 
mini-tablet (pink). Results are presented as means ± SE (n = 6). 
These observations are in agreement with the experimental data. Indeed, the RSV-B 
formulation, which is the only one that completely disintegrates, allowed the highest 
RSV concentration into the donor compartment (192.44 ± 37.40 µg/mL). Moreover, it 
should be considered that this concentration value is extremely high when compared to 
the reported water solubility of RSV (50 µg/mL), thus confirming the ability of the pro-
posed formulation to enhance drug solubility. Even more relevant is that RSV-B dosage 
form resulted in the highest observed flux value (22.26 ± 4.78 µg/cm2∙h−1). This result is of 
crucial importance, especially when compared to the flux obtained by administering 1 
mg/mL RSV solution: the RSV solution, despite having a concentration five-fold higher 
than the RSV-B formulation, produces a drug flux 1.6-fold lower. 
Consistent again with what was observed at the end of the experiments, RSV-C and 
RSV-D exhibited similar flux values while RSV-A had the lowest flux (1.95 ± 0.64 µg/cm2 ∙ 
h−1). However, for a more complete evaluation, Kp and Ac parameters (which are con-
centration independent) should be considered as the RSV concentration in the donor 
chamber is strictly correlated to the results obtained. By observing these values, it was 
evident that all four proposed formulations were able to act both as permeation (in-
creased Kp) and penetration (increased Ac) enhancers for RSV. Generally, RSV-A, RSV-B, 
RSV-C and RSV-D compositions increased the Kp value up to 4.3 (332.0%), 8.4 (740.6%), 
16.1 (1507.2%) and 2.7 (154.5%) times respectively when compared to RSV solution by 
itself. These results are highly significant and particularly satisfactory, especially when 
compared to those obtained by simply employing the CPEs (the best CPE was menthol, 
which enhances RSV permeability up to 3.5 times (247.4%)). In particular, RSV-B and 
RSV-C resulted in the highest Kp values (0.11566 ± 0.01422 cm/h and 0.22115 ± 0.02894 
cm/h, respectively, vs. 0.01376 ± 0.00311 cm/h for RSV solution). 
  
Pharmaceutics 2021, 13, 1370 15 of 26 
 
 
Table 6. Extrapolated RSV biopharmaceutical parameters (Js, Kp, tlag, De and Ac ± SE) and RSV 
concentration in the donor chamber after mini-tablets ex vivo evaluation. 











RSV 13.76 ± 3.11 0.01376 ± 0.00311 19 22.71 ± 5.54 0.02271 ± 0.00554 1000 (STD) 
RSV-A 1.95 ± 0.64 0.05944 ± 0.01981 NO 7.12 ± 1.58 0.21702 ± 0.07829 32.74 ± 4.60 
RSV-B 22.26 ± 4.78 0.11566 ± 0.01422 NO 25.19 ± 9.36 0.13087 ± 0.08584 192.44 ± 37.40 
RSV-C 3.70 ± 0.35 0.22115 ± 0.02894 NO 7.13 ± 1.07 0.42688 ± 0.09983 16.71 ± 2.17 
RSV-D 3.95 ± 0.55 0.03502 ± 0.00932 NO 81.18 ± 5.22 0.71939 ± 0.29361 112.85 ± 16.76 
To summarize: RSV-B and RSV-C appeared to be the best proposed formulations, 
and they were thus selected to be loaded with the best CPEs (menthol, lysine and urea). 
Five different CPE-containing compositions were produced by spray drying and, 
after characterization, were compressed into mini-tablets. The first significant difference 
between the CPE-loaded powders and the corresponding CPE-free formulations was re-
lated to the appearance. Indeed, the presence of the CPE, even a small amount (1-3% 
w/w), completely modified the obtained powders, which were more cohesive and com-
pact. The other evaluated characteristics for both the powders and the mini-tablets are 
reported in Table 7 and confirmed the suitability of the spray drying process and the re-
producibility of the tablet preparation method. 
Table 7. Characterization of the CPE-loaded spray dried powders (yield %, DL% and LE% ± SE) 
and the resulting sublingual mini-tablets (weight and drug content ± SE; n = 6). 
Sample 
Spray-Dried Powders Mini-Tablets 
Yield % DL% LE% Weight (mg) RSV (mg) 
RSV-B/M-3 73.2 13.40 ± 0.34 89.33 ± 2.27 30.43 ± 0.60 4.08 ± 0.08 
RSV-B/LYS-3 74.8 15.15 ± 1.41 101.02 ± 9.39 31.18 ± 1.07 4.72 ± 0.16 
RSV-B/U-3 75.4 15.03 ± 0.76 100.22 ± 5.07 30.20 ± 0.38 4.58 ± 0.06 
RSV-B/U-1 83.2 11.02 ± 1.33 73.47 ± 8.87 29.11 ± 0.31 4.41 ± 0.05 
RSV-C/LYS-3 73.2 15.75 ± 1.70 105.00 ± 11.33 31.38 ± 0.60 4.75 ± 0.09 
It is not surprising that the observed variations in terms of powders’ appearances 
resulted in different behaviors in terms of disintegration and RSV permeation. In partic-
ular, the CPE-loaded mini-tablets underwent only partial disintegration after permeation 
tests, and the solid residues were extremely crumbly to the touch. This generally resulted 
in a lower RSV concentration value and thus lower or at least similar flux, Kp and Ac 
values (Figure 5 and Table 8) than those of the corresponding CPE-free formulation. 
Moreover, the lower observed efficacy of the selected CPE when inserted into the for-
mulations, rather than when used as a solution together with RSV, could be due to the 
following considerations: menthol is a hydrophobic molecule insoluble in citrate buffer 
solution, and thus in these experimental conditions it is probably not solubilized and, 
consequently, it could not act; unexpectedly, lysine fails to be effective, perhaps due to its 
pH-dependent dissociation. The contribution of the PEG200 used in the previous experi-
ments probably increased the undissociated fraction available to act and favored the 
solubility of menthol. Finally, the unsatisfactory results obtained from the urea-loaded 
mini-tablets chould be due to the previously highlighted differences in terms of powder 
appearance. The cohesion as well as the incomplete disintegration of the urea-loaded 
powders/mini-tablets could also be due to the high moisturizing power of this permea-
tion enhancer. The drying process of the component’s mixture could potentially have 
determined interactions between these and urea, which should be deepened with further 
studies, or some excipients should simply be replaced. 
These results, unfortunately, preclude the possibility of merging the CPE-based ap-
proach and the innovative spray drying method proposed to enhance RSV permeation 
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through the sublingual tissue. In any case, it is important to point out that all the pro-
posed CPE-loaded formulations were able to enhance RSV sublingual permeability. In 
particular, RSV-B/M-3, RSV-B/LYS-3, RSV-B/U-3, RSV-B/U-1 and RSV-C/LYS-3 increased 
RSV permeability (Kp enhancement) up to 5.8 (483.1%), 12.1 (1108.9%), 3.8 (280.8%), 3.7 







Figure 5. (A,A1): Amount of RSV (mg/cm2) permeated from mini-tablets as a function of time (h). (B,B1): Kp; (C,C1) Ac 
parameters calculated after administration of RSV solution 1 mg/mL (black), RSV-B mini tablet vs. CPE-loaded RSV-B (A–
C) and RSV-C mini tablet vs CPE-loaded RSV-C (A1–C1). Results are presented as means ± SE (n = 6). 
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Table 8. Extrapolated RSV biopharmaceutical parameters (Js, Kp, tlag, De and Ac ± SE) and RSV concentration in the 














RSV-B/M-3 3.84 ± 1.61 0.08023 ± 0.05225 NO 
14.28 ± 
3.21 0.29870 ± 0.08721 47.82 ± 6.56 
RSV-B/LYS-3 7.96 ± 1.00 0.16635 ± 0.03022 NO 
2.84 ± 
1.00 0.05941 ± 0.02586 47.89 ± 8.25 
RSV-B/U-3 7.17 ± 1.77 0.05240 ± 0.01536 NO 23.94 ± 
6.78 
0.17504 ± 0.10061 136.76 ± 41.63 
RSV-B/U-1 3.82 ± 0.18 0.05127 ± 0.00547 NO 14.36 ± 4.91 0.19267 ± 0.07104 74.55 ± 8.35 
RSV-C/LYS-3 7.40 ± 0.96 0.22531 ± 0.02123 NO 
5.90 ± 
2.16 0.17979 ± 0.06396 32.83 ± 4.44 
To summarize, the RSV-B composition resulted in the best mini-tablet formulation 
due to the following considerations: the tablet appears totally disintegrated at the end of 
the permeation experiments and additionally the disintegration process begins instantly 
as soon as the formulation is put into contact with the donor fluid; the RSV-B formulation 
allows high RSV concentration in the donor compartment, thus contrasting the 
well-known poor water solubility of RSV and consequently contributing to the obtain-
ment of an effective concentration gradient; the observed drug flux is higher than that 
observed by administering RSV solution 1 mg/mL (Figure 6), although drug concentra-
tion in the donor compartment is about 1/5 (0.192 mg/mL for the RSV-B formulation vs. 1 
mg/mL for the RSV solution); and the RSV-B mini-tablets promote immediate drug ab-
sorption and immediate establishment of the steady-state equilibrium (no lag time). All 
these factors might contribute to determining high patient compliance and potentially 
therapeutic success. Indeed, after in vivo administration high blood concentrations of 
RSV could be achieved as the mini-tablet disintegration could lead to a sublingual highly 
concentrated RSV solution which is in close contact with a great surface of absorption 
(tongue ventral surface together with floor of the mouth are about 26.5 cm2) [17]. 
 
Figure 6. RSV (mg/cm2) permeated as a function of time (h) after administration of 1 mg/mL RSV 
solution (black) and RSV-B mini-tablet (red). 
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3.3. Characterization of RSV-B Powder and Mini-Tablets 
As already highlighted, the RSV-B composition was the most promising one both in 
terms of enhancement of RSV solubility and thus flux and permeability, as well as in 
terms of suitability as a fast-disintegrating sublingual formulation. In view of the ob-
tained promising results, the selected composition was then subjected to further evalua-
tions. 
In particular, the RSV-B powder was investigated by SEM, FTIR in ATR mode and 
XRD analyses. 
SEM images were recorded to verify sample homogeneity as well as the size and the 
morphology of the spray-dried microparticles which make up the obtained powder. 
Figure 7 shows different images of the RSV-B powder, recorded at various magni-
fications. As is observable, the analyzed sample is homogeneous with microparticles 
ranging from 15 to 20 µm and linked by a web-like structure, probably due to the pres-
ence of PVP K90. 
 
Figure 7. Morphology of RSV-B spray-dried powder evaluated by scanning electron microscopy (SEM) at different 
magnifications in order to verify microparticles’ diameter and sample uniformity. 
Furthermore, FTIR spectra were collected in ATR mode to evaluate any drug–
excipients interaction. As shown in Figure 8, the presence of PVP K90 allows for the 
hiding of RSV peaks. Analyzing the recorded spectra in the range from 1550 to 1620 cm-1 , 
it is possible to notice the presence of RSV peaks without any chemical shift. Moreover, at 
1650 cm-1 a mathematical sum of RSV and PVP K90 peaks further confirmed that no 
chemical interactions occur between the natural compound and the employed polymer. 




Figure 8. ATR-FTIR spectra of pure RSV (black), PVP K90 (red) and RSV-B powder (green). 
Finally, the last crucial characterization performed on the RSV-B-spray-dried pow-
der was aimed at the evaluation of RSV physical state (crystalline or amorphous) by XRD 
analysis. The obtainment of the drug in its amorphous form is a key point aimed at im-
proving drug solubility and consequently permeability, particularly for poorly wa-
ter-soluble molecules such as RSV. Additionally, from a thermodynamic point of view, 
an amorphous form is not stable and could easily evolve again into the crystalline form, 
so it is also crucial to assess its stability over time. In Figure 9 the obtained diffractograms 
for both RSV and RSV-B formulation are reported. As is observable, panel A is charac-
terized by the peaks of the starting employed crystalline, RSV, while panel B is charac-
terized by the absence of the previously observed peaks, being of RSV-B powder. This is 
due to the complete amorphization of RSV when spray-dried together with the selected 
excipients. Furthermore, panel C shows that after 6 months of storage of the prepared 
powder (at room temperature, in the dark) the loaded RSV remains in the amorphous 
form. This is probably due to the efficacy of PVP K90 in preventing drug crystallization 
by enhancing the physical stability of the amorphous form [46,47]. These results are par-
ticularly interesting and satisfactory, as well as being perfectly coherent with the ob-
served enhancement of RSV solubility for the RSV-B formulation. 




Figure 9. Diffractograms of (A) pure RSV, (B) RSV-B immediately after preparation and (C) RSV-B after a 6-month stor-
age period. 
Moreover, the prepared RSV-B mini-tablets were subjected to disintegration and 
dissolution studies. 
The disintegration time (DT) is a critical attribute to be optimized for the aim of 
preparing an effective fast-disintegrating sublingual formulation. Generally, it is re-
ported that the observable DT, by using a disintegration apparatus, should be less than 30 
sec for orally disintegrating tablets [29,53,54]. In this work, the DT was evaluated by two 
different methods. The first one, as the literature reports, consists in the use of a large 
disintegration medium volume (900 mL) at 37 ± 0.5°C [16]. In these experimental condi-
tions, the calculated DT was 4.06 ± 0.39 sec. Moreover, to permit an easy evaluation, a 
visual disintegration experiment was conducted by recording both photographs and 
videos of the disintegration process. This type of test was performed by inserting RSV-B 
mini-tablets into glass crucibles and soaking them with 1 mL of prewarmed (37 ± 0.5°C) 
citric buffer solution (pH 5.5). Indeed, the use of such a small volume is more repre-
sentative as it mimics the in vivo conditions observable after sublingual administration 
(the mini-tablet will be in contact with a small salivary volume). This test confirms the 
previously obtained results in terms of DT (Figure 10). As the disintegration process was 





B)           RSV-B (t=0)                C)             RSV-B (t=6 months) 
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and, as a consequence, in the supplementary materials two videos are reported (normal 
speed and slow motion) to better illustrate the disintegration of the proposed RSV-B 
mini-tablets. However, it must be considered that the whole experiment required at least 
8 s from the beginning of soaking to complete disintegration. Indeed, in any case the 
proposed formulation meets the criteria for a sublingual fast-disintegration dosage form 
(DT < 30 s). 
 
Figure 10. In vitro disintegration visual test: (A) sequence of photographs; (B) highlights of the starting and end points 
(for a more complete result please check the videos in the supplementary material). 
Another parameter to be evaluated, especially for poorly water-soluble molecules, is 
drug dissolution rate. The dissolution studies were performed according to the literature, 
which reports that the percentage of released drug from sublingual tablets must exceed 
80.0% in 15 min [54,55]. Results are reported in Figure 11 as percentage of RSV dose re-
leased over time (min). As is observable, after 15 min 88.94 ± 8.19% of the RSV dose was 
*t = 0 
**End Point 
A) 
*t = 0 
**End Point 
B) 
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released, thus confirming the goodness of the proposed formulation. Furthermore, the 
whole amount of RSV was released at the end of the dissolution tests (25 min). 
 
Figure 11. In vitro dissolution profile: RSV released (% of dose) as a function of incubation time 
(min). Results are presented as means ± SE (n = 6). 
To conclude, the proposed RSV-B mini-tablets should be suitable and effective as a 
sublingual fast-disintegrating dosage form as they meet all the quality criteria of a useful 
sublingual DDS: 
• Ability to completely and quickly disintegrate to ensure good patient compliance 
(DT: 4.06 ± 0.39 s); 
• Ability to quickly release the embedded drug thus ensuring the formation of a con-
centrated in situ solution (RSV released after 15 min: 88.94 ± 8.19%); 
• Ability to promote drug solubility (RSV concentration in the donor chamber: 192.44 ± 
37.40 µg/mL); 
• Ability to ensure a high drug flux through the administration site in order to max-
imize its entrance into the bloodstream allowing systemic effects (RSV flux after 
RSV-B administration: 22.26 ± 4.78 µg/cm2∙h−1); 
• Ability to promote an immediate absorption, allowing a fast achievement of the de-
sired effects (lag time absence; 8.41-fold increased Kp value with respect to RSV so-
lution 1 mg/mL). 
4. Conclusions 
In this work, the low aptitude of RSV to cross the sublingual mucosa was success-
fully overcome by two different strategies. On one hand, six different CPEs (SDS, SDC, 
Transcutol®, urea, lysine and menthol) were tested and they all were useful in promoting 
sublingual RSV permeation. In particular, menthol, lysine and urea were the best hy-
drophobic, hydrophilic pH-dependent and hydrophilic pH-independent CPEs, respec-
tively. On the other hand, the spray drying technique was used as an innovative ap-
proach to prepare RSV-loaded powders suitable for direct compression in order to obtain 
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sublingual mini-tablets. Four different compositions named RSV-A, RSV-B, RSV-C and 
RSV-D containing high amounts of RSV (15% w/w) were prepared by varying the excip-
ients ratios (PVP K90, PEG200, sorbitol and propylene glycol). RSV was proven to be a 
good candidate for the spray drying process as the operating conditions do not com-
promise its stability. The obtained powders were homogenous and the spray drying 
atomization yield was particularly high (≈ 70%). Moreover, the obtained pharmaceutical 
powders allowed for the creation of uniform mini-tablets which were used for the ex vivo 
permeation evaluations. All the proposed formulations were able to enhance RSV sub-
lingual permeation (increments in terms of Kp) and accumulation in the mucosal tissue 
(increments in terms of Ac). As data suggested, the RSV-B formulation emerged as the 
most promising one while the RSV-C composition allowed for the highest observed in-
crement in terms of Kp. These chosen compositions were then added to the best CPEs, 
thus preparing CPE-loaded powders and mini-tablets. Unfortunately, these formulations 
gave unsatisfactory results both in terms of RSV solubility, drug flux and Kp values en-
hancement. These results thus preclude the possibility of converging the two proposed 
approaches (the chemical and the technological ones) to promote RSV sublingual per-
meation. As the RSV-B composition was the most promising one, it was further analyzed 
in order to demonstrate its usefulness as a fast-disintegrating sublingual formulation. In 
particular, SEM analysis highlighted the particle size homogeneity of the spray-dried 
powder (≈ 15-20 µm), FTIR spectra depicted that no interactions occur between RSV and 
PVP K90 and the XRD evaluation showed the complete and stable amorphization of the 
loaded RSV after 6 months of storage. Finally, its effectiveness as a fast-disintegrating 
sublingual dosage form was assessed by the evaluation of the disintegration time (4.06 ± 
0.39 sec) and the percentage of RSV dose released after 15 min (88.94 ± 8.19%). The results 
obtained perfectly fit with the reference values reported in the literature. 
Supplementary Materials: The following are available online at 
www.mdpi.com/1999-4923/13/9/1370/s1, Figure S1: RSV permeation profile: amount of RSV per-
meated per unit area as a function of incubation time, Figure S2: RSV permeation profile in pres-
ence of sodium dodecyl sulfate as CPE (RSV:SDS = 5:1): amount of RSV permeated per unit area as 
a function of incubation time, Figure S3: RSV permeation profile in presence of sodium dehy-
drocolate as CPE (RSV:SDC = 5:1): amount of RSV permeated per unit area as a function of incuba-
tion time, Figure S4: RSV permeation profile in presence of Transcutol® as CPE (RSV:T = 5:1): 
amount of RSV permeated per unit area as a function of incubation time, Figure S5: RSV permea-
tion profile in presence of urea as CPE (RSV:U = 5:1): amount of RSV permeated per unit area as a 
function of incubation time, Figure S6: RSV permeation profile in presence of lysine as CPE 
(RSV:LYS = 5:1): amount of RSV permeated per unit area as a function of incubation time, Figure 
S7: RSV permeation profile in presence of menthol as CPE (RSV:M = 5:1): amount of RSV perme-
ated per unit area as a function of incubation time, Figure S8: Appearance of A) RSV-A- and B) 
RSV-C-spray-dried powders, Figure S9: Appearance of RSV-loaded sublingual mini-tablets, Video 
S1: Visual disintegration assay of RSV-B mini-tablets (normal speed), Video S2: Visual disintegra-
tion assay of RSV-B mini-tablets (slow motion). 
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